A Lower Baseline Urinary Glucose Excretion Predicts a Better Response to the Sodium Glucose Cotransporter 2 Inhibitor
Diabetes & Metabolism Journal
;
: 898-905, 2019.
Article
in English
| WPRIM
| ID: wpr-785701
ABSTRACT
We aimed to identify the clinical variables associated with a better glucose-lowering response to the sodium glucose cotransporter 2 inhibitor ipragliflozin in people with type 2 diabetes mellitus (T2DM). We especially focused on urinary glucose excretion (UGE). This was a single-arm multicenter prospective study. A total of 92 people with T2DM aged 20 to 70 years with glycosylated hemoglobin (HbA1c) levels ≥7.0% and ≤9.5% were enrolled. Ipragliflozin (50 mg) was added to the background therapy for these people for 12 weeks. After 3 months treatment with ipragliflozin, the mean HbA1c levels were decreased from 7.6% to 6.9% and 62.0% of the people reached the HbA1c target of less than 7.0% (P<0.001). In addition, body weight, blood pressure, and lipid parameters were improved after ipragliflozin treatment (all P<0.001). The baseline HbA1c (r=0.66, P<0.001) and morning spot urine glucose to creatinine ratio (r=−0.30, P=0.001) were independently associated with the HbA1c reduction. Ipragliflozin treatment for 12 weeks improves glycemic control and other metabolic parameters. A higher HbA1c and lower UGE at baseline predicts a better glucose-lowering efficacy of ipragliflozin.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Sodium
/
Blood Pressure
/
Body Weight
/
Glycated Hemoglobin
/
Prospective Studies
/
Creatinine
/
Diabetes Mellitus, Type 2
/
Sodium-Glucose Transporter 2
/
Glucose
/
Glycosuria
Type of study:
Controlled clinical trial
/
Observational study
/
Prognostic study
/
Risk factors
Language:
English
Journal:
Diabetes & Metabolism Journal
Year:
2019
Type:
Article
Similar
MEDLINE
...
LILACS
LIS